(RTTNews) - Prime Medicine, Inc.(PRME), Tuesday announced the initiation of its preclinical program for the treatment of Alpha-1 Antitrypsin Deficiency or AATD using its proprietary Prime Editing ...
The firm thinks the data were “a clear win for Beam in AATD,” which it views as “an underappreciated market opportunity,” the analyst told investors. Effectively assess a stock's risks and ...
(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback